Innovative antibiotics eligible for FDA priority review Treatcommunity-acquired pneumonia

CABP is pneumonia caused by an infection outside a medical facilityThe most common pathogens are streptococcus pneumoniae, haemophilus influenzae type flue goecole and atypical bacteria (e.gchlamydia pneumoniae, mycoplasma pneumoniae, Legionella)Due to increased bacterial resistance and aging society, many CAPs can lead to serious and even fatal illnesses for the elderly and patients with weak healthMelinta, an innovative broad-spectrum antibiotic that has been approved by the FDA to treat acute bacterial skin and skin structure infections (ABSSSI)This antibiotic is effective against both gram-negative and positive bacteria, and can treat methicillin-resistant Staphylococcus aureus (MRSA)It has been granted FDA-awarded qualified infectious disease products (QIDP)the application is based on the results of a randomized double-blind phase 3 clinical trialIn this trial, PATIENTS WITH CABP were treated with Baxdela or moxifloxacinThe results show that Baxcela meets the non-disadvantage standard in efficacy compared with MoxishaAt the same time, Baxdela exhibits good safety and tolerance" cabPA remains a serious challenge for health care workers due to increased bacterial resistance and the aging of societyWe need new treatment options," said DrSue Cammarata, Chief Medical Officer of Melinta, "Baxdela's effectiveness in the most common bacterial pathogens in CABP suggests that it can play an important role in the treatment of this life-threatening disease." We look forward to working with the FDA to bring this treatment option to CABP patients as soon as possibleReferences:.®Retrieved June 19, 2019, from http:// Retrieved June 19, 2019, from https://